Drug Patents owned by Kala Pharms Inc

1. Drug name - EYSUVIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11219596 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10857096 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10945948 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10940108 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US9532955 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US9737491 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US9056057 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US9827191 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10058511 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US10993908 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10688045 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US9393213 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US10646436 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 26, 2023

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 26 October, 2020

Treatment: A method for treating dry eye in a patient; A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; Administration to the eye of a patient for treatment of dry eye condition

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.25% SUSPENSION/DROPS;OPHTHALMIC Prescription

2. Drug name - INVELTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9056057 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US9532955 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US10058511 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US11219597 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10864219 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US9737491 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US9827191 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10688045 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10646437 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US9393213 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 22 August, 2018

Treatment: A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; A method of reducing post-surgical pain following ocular surgery; A method of treating postoperative inflammation following ocular surgery; A method for treating ocular inflammation; A method for treating inflammation and/or other disorders in an eye of a patient

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
1% SUSPENSION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in